Comparative Pharmacology
Head-to-head clinical analysis: MEPIVACAINE HYDROCHLORIDE versus XYLOCAINE DENTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPIVACAINE HYDROCHLORIDE versus XYLOCAINE DENTAL.
MEPIVACAINE HYDROCHLORIDE vs XYLOCAINE DENTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepivacaine hydrochloride is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by binding to sodium channels in the neuronal cell membrane, thereby stabilizing the membrane and preventing depolarization.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking the initiation and conduction of nerve impulses.
1-2% solution, 5-20 mL local infiltration or nerve block, maximum 400 mg per procedure.
Xylocaine Dental (lidocaine HCl 2% with epinephrine 1:100,000 or 1:50,000): For infiltration/inferior alveolar nerve block, maximum dose 3.4 mg/kg (4.5 mg/kg with epinephrine 1:100,000) not to exceed 300 mg; usual adult dose: 1–5 mL (20–100 mg) administered via oral submucosal injection.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours). In neonates and patients with hepatic dysfunction, half-life may be prolonged up to 8–10 hours.
1.5–2 hours in adults with normal hepatic function. Prolonged to 2–3 hours in patients with hepatic impairment or congestive heart failure; may exceed 5 hours in severe hepatic disease.
Primarily hepatic metabolism via amidase enzymes; ~95% excreted as metabolites in bile and feces, <5% unchanged in urine.
Renal excretion of unchanged drug and metabolites accounts for >95% of the dose. Approximately 70% is excreted as the metabolite 4-hydroxy-2,6-xylidine; less than 10% is unchanged lidocaine. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic